Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Biosimilars Launches Strategy

Samsung Bioepis Toasts First Bevacizumab Biosimilar In Korea

Onbevzi Rival To Avastin Launched By Partner Boryung Pharmaceutical

  • News

Executive Summary

Samsung Bioepis has expanded its portfolio of biosimilar products in its domestic South Korea, with the launch of bevacizumab via partner Boryung Pharmaceutical.

You may also be interested in...



Celltrion Confirms EU Bevacizumab Filing

Celltrion has confirmed that it has now filed its CT-P16 proposed bevacizumab rival to Avastin with the European Medicines Agency, having previously submitted it to regulators in both Korea and the US.

Samsung Bioepis Urges Oncology Systems To Share Biosimilar Success Stories

Prescribers must better understand how biosimilars work and why they are safe to use, in order to ensure continued biosimilar uptake, Samsung Bioepis believes.

Samsung Bioepis Scoops First EU Lucentis Biosimilar As 2022 Date Looms

Samsung Bioepis has seen a positive opinion in the EU for its Byooviz (ranibizumab) biosimilar treatment for wet age-related macular degeneration turned into final approval by the European Commission. The company is also leading the pack in the US.

Table

View full table

Related Content

Generics Bulletin

Topics

Related Companies

Tags:
Biosimilars Launches Strategy
UsernamePublicRestriction

Register

GB151219

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By